ReviewMethods in molecular biology (Clifton, N.J.)2026
Liquid Biopsies and Molecular Imaging for Precise Cancer Management.
Review in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last years, several body fluid-based tests, able to detect molecular alterations derived from tumors, have been proposed, and numerous others are in continuous development. These tests, commonly referred to as "liquid biopsies," encompass a wide spectrum of diagnostic procedures, such as circulating tumor cells (CTCs), cell-free circulating tumor DNA (ctDNA), circulating tumor-derived exosome, and other biomarkers, whose detection can offer precious information about tumor volume and disease status. Nevertheless, these novel biomarkers have limited sensitivity and specificity when used alone. In this scenario, molecular imaging with positron emission tomography (PET), due to its wide availability and the consolidated role in cancer patients' management, could be coupled with liquid biopsy for cancer characterization, patient stratification, and the early detection of recurrence. In this chapter, we will focus on studies that combine liquid biopsy and PET-based parameters across different cancer types and therapeutic settings.
Indexed as
Identifiers
42426456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.